Therefore, the greatest medicinal potential for neurodegeneration after stroke and animal ischemia should have molecules with pleiotropic activity, especially those with anti-amyloid, anti-tau protein and anti-dementia properties, as well as those that reduce oxidative stress and neuroinflammation [102]. The gene discussed is MAPT; the disease is dementia.